Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy
Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy: Exploration of Cognitive, Affective, and Physiological Mechanisms
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Tallahassee, Florida, Forenede Stater, 32306-2570
- FSU College of Social Work
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- chronic pain diagnosis (ICD-9 diagnoses 338.xx)
- treatment with prescription opioids for > 3 months
Exclusion Criteria:
- prior mindfulness training
- persons who are experiencing acute opioid withdrawal
- suicidal ideation
- psychosis
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Mindfulness-orienteret Recovery Enhancement
|
MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction.
MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
|
|
Aktiv komparator: Conventional Support Group (SG)
|
The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse.
The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual.
The SG consists of eight, weekly, two-hour sessions.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain severity, pain functional interference
Tidsramme: Baseline, immediately following treatment, and at 3 month follow-up
|
Change in pain severity, functional interference, and relief from pain treatments measured on the Brief Pain Inventory-Short Form.
|
Baseline, immediately following treatment, and at 3 month follow-up
|
|
Opioid craving
Tidsramme: Baseline, immediately following treatment, and at 3 month follow-up
|
Change in opioid craving as measured by the Obsessive-Compulsive Drug Use Scale and a single-item measure of instantaneous craving.
|
Baseline, immediately following treatment, and at 3 month follow-up
|
|
Opioid misuse behaviors
Tidsramme: Baseline, immediately following treatment, and at 3 month follow-up
|
Change in opioid misuse behaviors as measured by the Current Opioid Misuse Measure
|
Baseline, immediately following treatment, and at 3 month follow-up
|
|
Well-being
Tidsramme: Baseline, immediately following treatment, and at 3 month follow-up
|
Change in well-being as measured by the WHO-5
|
Baseline, immediately following treatment, and at 3 month follow-up
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Attentional bias
Tidsramme: Baseline and immediately following treatment
|
Change in attentional bias as measured by a dot probe task
|
Baseline and immediately following treatment
|
|
Psychophysiological cue-reactivity
Tidsramme: Baseline and immediately following treatment
|
Change in psychophysiological cue-reactivity
|
Baseline and immediately following treatment
|
|
Emotional response inhibition
Tidsramme: Baseline and immediately following treatment
|
Change in emotional response inhibition
|
Baseline and immediately following treatment
|
|
Pain coping strategies
Tidsramme: Baseline, intervention midpoint, and immediately following treatment
|
Change in reinterpretation of pain sensations, catastrophizing, and suppression.
|
Baseline, intervention midpoint, and immediately following treatment
|
|
Anhedonia
Tidsramme: Baseline and immediately following treatment
|
Change in anhedonia
|
Baseline and immediately following treatment
|
|
Fear of pain
Tidsramme: Baseline and immediately following treatment
|
Change in fear of pain
|
Baseline and immediately following treatment
|
|
Mindfulness
Tidsramme: Baseline, intervention midpoint, and immediately following treatment
|
Change in mindfulness measured by the Five-Facet Mindfulness Questionnaire and the Toronto Mindfulness Scale
|
Baseline, intervention midpoint, and immediately following treatment
|
|
Positive reappraisal
Tidsramme: Baseline and immediately following treatment
|
Change in positive reappraisal
|
Baseline and immediately following treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Eric L Garland, PhD, Florida State University
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- DA032517-01
- R03DA032517 (U.S. NIH-bevilling/kontrakt)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .